It appears more likely than ever that both sides of Congress will soon follow through with a response to America's addiction crisis. That's the good news. The other news: While the bill that was approved 407-5 Friday by the U.S. House represents important progress in the federal approach to addiction, it does not accomplish all that it could, or all that is needed. We sent emails to House and Senate offices late last week with information and resources on the topic of opioids—the class of drugs that includes heroin, fentanyl and prescription pain medications, and that has fueled an epidemic of overdose deaths. In the messages, we expressed support for the conference committee report on the Comprehensive Addiction and Recovery Act (CARA). Recognizing the revised bill’s shortcomings, we also alluded to future Congressional work on this issue, which we hope to see. While many advocates are celebrating the bill's passage by the House, others have decided to oppose the current version of CARA—encouraging the President and members of the Senate to reject the bill unless it is strengthened. Indeed, CARA presents a classic political conundrum. Support something that falls short of the ideal? Or, voice opposition that could contribute to the worst-case scenario—getting nothing passed at all?